DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Japanese encephalitis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJapanese encephalitis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for japanese encephalitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 6 receptor (IL6R) — IL6R is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QY5 · 3.1 Å · ligand none (apo structure). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Virology Journal · 2011 · 59 citations · open access
Transcriptomic profile of host response in Japanese encephalitis virus infection
AbstractBACKGROUND: Japanese encephalitis (JE) is one of the leading causes of acute encephalopathy with the highest mortality rate of 30-50%. The purpose of this study was to understand complex biological processes of host response during the progression of the disease. Virus was subcutaneously administered in mice and brain was used for whole genome expression profiling by cDNA microarray. RESULTS: The comparison between viral replication efficiency and disease progression confirms the active role of host response in immunopathology and disease severity. The histopathological analysis confirms the severe damage in the brain in a time dependent manner. Interestingly, the transcription profile reveals significant and differential expression of various pattern recognition receptors, chemotactic genes and the activation of inflammasome. The increased leukocyte infiltration and aggravated CNS inflammation may be the cause of disease severity. CONCLUSION: This is the first report that provides a detailed picture of the host transcriptional response in a natural route of exposure and opens up new avenues for potential therapeutic and prophylactic strategies against Japanese encephalitis virus.
The Keio Journal of Medicine · 1953 · 0 citations · open access
CHEMOTHERAPEUTIC EFFECT OF N1-DODECANOYL-N4-ACETYL-4-AMINONAPHTHALENE-SULFONAMIDE-(1) ON NEUROTROPIC VIRUSES
Abstract(1) PANS-No. 610 shows a remarkable effect on the Japanese encephalitis virus in vitro and in vivo. It is effective even at a longer interval after the inoculation of the virus.(2) The drug shows a weak effect in vitro and in vivo on the Lansing virus.(3) The drug possesses a comparatively low toxicity.(4) It is assumed that the effect of the drug on the Japanese encephalitis virus might be caused by its neurotropy, cerebrotropy and penetration-power into cells in host, related to its surfactant properties.(5) The drug is of promise for the treatment of the diseases caused by the Japanese encephalitis virus.(6) It may be claimed that the drug is the only compound which has been confirmed to have chemotherapeutic effects on patients suffering from the so-called small virus such as the Japanese encephalitis virus.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
